40 results on '"Hogan, William J."'
Search Results
2. Pulmonary function as a continuum of risk: critical care utilization and survival after allogeneic hematopoietic stem cell transplantation - a multicenter cohort study
3. EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant
4. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD
5. The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
6. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
7. Adjusting diffusing capacity for anemia in patients undergoing allogeneic HCT: a comparison of two methodologies
8. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis
9. A Day 14 Endpoint for Acute GVHD Clinical Trials
10. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD
11. Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent
12. Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant
13. Lung Injury Prediction Model in Bone Marrow Transplantation: A Multicenter Cohort Study
14. Flares of Acute Graft-Versus-Host Disease (GVHD): A Mount Sinai Acute GVHD International Consortium (MAGIC) Analysis
15. Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents
16. Severe Late Agranulocytosis Post-Allogeneic Stem Cell Transplant during Tacrolimus Taper
17. Factors Predicting Survival in Patients with TP53-Mutated Myeloid Neoplasms Following Allogeneic Stem Cell Transplant
18. Ibrutinib for Therapy of Steroid-Refractory Chronic Graft Vs. Host Disease: A Multicenter Real-World Analysis
19. Coronary Artery Calcium As a Predictor of Non-Relapse Mortality and Overall Survival in Patients Undergoing Post-Transplant Cyclophosphamide As Gvhd Prophylaxis
20. Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms
21. Donor Search and Selection Strategy to Facilitate Comparable Transplant Rates across Donor Search Prognosis Groups: A Report from the BMT CTN 1702 Trial
22. The Mount Sinai Acute Gvhd International Consortium (MAGIC) Model: An Integrated Clinical and Biomarker Grading System for Acute Graft-Versus-Host Disease (GVHD)
23. Chronic Graft-Versus-Host Disease Leptomeningitis Following Allogeneic Stem Cell Transplant.
24. Impact of Wilms Tumor (WT1) Mutation on Relapse and Overall Survival in Acute Myeloid Leukemia Patients Following Allogenic Stem Cell Transplantation
25. Outcomes of HLA-DPB1 Mismatch in Patients Receiving Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prophylaxis
26. Pilot Prospective Study of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Vexas Syndrome
27. The MAGIC Algorithm Probability Predicts Treatment Response and Long-Term Outcomes to Second-Line Therapy for Acute Gvhd
28. Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms
29. Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases.
30. Mast cell cytomorphology and treatment outcome in mast cell leukemia.
31. Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcome.
32. Venetoclax plus hypomethylating agents in DDX41‐mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients.
33. Experience With an Optical Character Recognition Search Application for Review of Outside Medical Records
34. Differences in acute graft-versus-host disease (GVHD) severity and its outcomes between Black and White patients
35. Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma
36. Surrogates of endothelial injury predict survival after post-transplant cyclophosphamide
37. Amphiregulin, ST2, and REG3α Biomarker Risk Algorithms as Predictors of Non-Relapse Mortality in Patients with Acute GVHD
38. Clinicopathologic correlates and prognostic impact of lymphoid aggregates in patients with myelodysplastic syndromes.
39. Prognostic impact of SF3B1 mutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative cases.
40. FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)( DEK::NUP214 ): The Mayo Clinic experience.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.